Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:14:54 EDT Mon 30 Jun 2025
Enter Symbol
or Name
USA
CA



Q:REGN - REGENERON PHARMACEUTICALS INC - https://www.regeneron.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
REGN - Q0.5520.00·528.000.4525.00+4.000.81,013.2529,28721,209520.21  525.92  518.901,211.1999  476.486918:48:07Jun 2615 min RT 2¢

Recent Trades - Last 10 of 21209
Time ETExPriceChangeVolume
18:48:07Q516.20-4.801
18:38:25Q516.20-4.805
18:34:21Q525.004.001
18:27:01Q515.02-5.981
18:26:35Q525.004.001
18:23:09Q525.004.001
18:20:53Q525.004.004
18:13:45Q524.003.004
18:13:16Q525.004.001
18:04:52Q525.004.001

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-26 16:05U:REGNNews ReleaseRegeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
2025-06-24 07:30U:REGNNews ReleaseRegeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
2025-06-20 01:01U:REGNNews ReleaseDupixent(TM) (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
2025-06-15 11:21U:REGNNews ReleaseDupixent(TM) (dupilumab) Demonstrated Superiority Over Xolair(TM) (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
2025-06-13 16:23U:REGNNews Release23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process
2025-06-07 18:30U:REGNNews ReleaseDupixent(TM) (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
2025-06-02 07:06U:REGNNews ReleaseRegeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
2025-06-02 07:00U:REGNNews ReleaseInterim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass
2025-05-31 08:05U:REGNNews ReleaseLibtayo(TM) (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
2025-05-30 01:00U:REGNNews ReleaseItepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
2025-05-22 17:00U:REGNNews ReleaseLinvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma
2025-05-19 07:08U:REGNNews ReleaseRegeneron Enters into Asset Purchase Agreement to Acquire 23andMe(TM) for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
2025-05-19 07:04U:REGNNews ReleaseRegeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale
2025-05-16 11:25U:REGNNews Release75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition
2025-05-15 14:03U:REGNNews ReleaseRegeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
2025-05-01 09:30U:REGNNews ReleaseRegeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo(TM) (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination
2025-05-01 09:00U:REGNNews ReleaseDupixent(TM) (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases
2025-04-29 06:30U:REGNNews ReleaseRegeneron Reports First Quarter 2025 Financial and Operating Results
2025-04-28 07:02U:REGNNews ReleaseLynozyfic(TM) (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma
2025-04-28 07:01U:REGNNews ReleaseEYLEA HD(TM) (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease